EPHA2: As mentioned above, sorafenib inhibits the expression of HIF-2α, VEGFA, and EPHA2 and could serve as an effective adjunct treatment for HCC following HIFU ablation, suggesting that sorafenib may help reduce the relapse rate in residual tumors after insufficient HIFU treatment [70]. The gene discussed is EPHA2; the disease is hepatocellular carcinoma.